Interferon-γ sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-κB activation

Cancer Science

Volumn 98, Issue 11, 2007, Pages 1758-1766

  Chung, Chan ^a   Park, Sung Gyoo ^a   Park, Young Min ^b   Joh, Jae Won ^c   Jung, Guhung ^a  

^a Seoul National University   (South Korea)

^b Bundang Jesaeng Hospital   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GAMMA INTERFERON; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CELL STRAIN HEPG2; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIZATION; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INHIBITION KINETICS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VIRUS INHIBITION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FLUOROURACIL; GENES, REPORTER; HEPATITIS B VIRUS; HUMANS; INTERFERON-BETA; LIVER NEOPLASMS; LUCIFERASES; NF-KAPPA B; RESTRICTION MAPPING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 34748924226     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00591.x     Document Type: Article

References (67)

1. Zuckerman AJ. More than third of world's population has been infected with hepatitis B virus. BMJ 1999; 318: 1213.
2. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-56.
3. Feitelson MA. Hepatitis B virus in hepatocarcinogenesis. J Cell Physiol 1999; 181: 188-202.
4. Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P. Molecular basis for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000; 10: 211-31.
5. Santoro MG, Rossi A, Amici C. NF-κB and virus infection: Who controls whom. EMBO J 2003; 22: 2552-60.
6. Kim WH, Hong F, Jaruga B et al. Additive activation of hepatic NF-κB by ethanol and hepatitis B protein X (HBX) or HCV core protein: Involvement of TNF-α receptor 1-independent and -dependent mechanisms. FASEB J 2001; 15: 2551-3.
7. Su F, Theodosis CN, Schneider RJ. Role of NF-κB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. J Virol 2001; 75: 215-25.
8. Yun C, Um HR, Jin YH et al. NF-κB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Cancer Lett 2002; 184: 97-104.
9. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002; 109 (Suppl): S81-96.
10. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-8.
11. Pikarsky E, Porat RM, Stein I et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
12. Greten FR, Eckmann L, Greten TF et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
13. Arlt A, Gehrz A, Muerkoster S et al. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243-51.
14. Mabuchi S, Ohmichi M, Nishio Y et al. Inhibition of NFκaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004; 279: 23-477-85.
15. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001; 11: S22-6.
16. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-811.
17. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001; 7: 3269-75.
18. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60: 5451-5.
19. Wang W, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 1999; 18: 4554-63.
20. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5: 119-27.
21. Dong QG, Sclabas GM, Fujioka S et al. The function of multiple IκB: NF-κB complexes in the resistance of cancer cells to taxol-induced apoptosis. Oncogene 2002; 21: 6510-19.
22. Arlt A, Schafer H. NFκB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 2002; 40: 336-47.
23. Arlt A, Vorndamm J, Breitenbroich M et al. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001; 20: 859-68.
24. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309.
25. Patel NM, Nozaki S, Shortle NH et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 2000; 19: 4159-69.
26. Kikuchi E, Horiguchi Y, Nakashima J et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res 2003; 63: 107-10.
27. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E. Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells. Cancer Res 2004; 64: 8167-76.
28. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be. NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene 2003; 22: 8961-82.
29. Zhan Q, Antinore MJ, Wang XW et al. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 1999; 18: 2892-900.
30. 2/M cell cycle checkpoint. Proc Natl Acad Sci USA 1999; 96: 3706-11.
31. Jin S, Antinore MJ, Lung FD et al. The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression. J Biol Chem 2000; 275: 16 602-8.
32. De Smaele E, Zazzeroni F, Papa S et al. Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling. Nature 2001; 414: 308-13.
33. Zazzeroni F, Papa S, Algeciras-Schimnich A et al. Gadd45β mediates the protective effects of CD40 costimulation against Fas-induced apoptosis. Blood 2003; 102: 3270-9.
34. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
35. Johnson PJ, Williams R, Thomas H, Sherlock S, Murray-Lyon IM. Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1978; 1: 1006-9.
36. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62: 479-83.
37. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: Current status and future directions. Cancer Treat Rev 1988; 15: 1-31.
38. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: A review. Eur J Cancer 2004; 40: 1474-84.
39. Huang CC, Wu MC, Xu GW et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992; 84: 262-4.
40. Chou YY, Cheng AL, Hsu HC. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol 1997; 12: 569-75.
41. Wheelock EF. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965; 149: 310-11.
42. Abend JR, Low JA, Imperiale MJ. Inhibitory effect of IFN-γ on BK virus gene expression and replication. J Virol 2007; 81: 272-9.
43. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8.
44. Park SG, Ryu HM, Lim SO, Kim YI, Hwang SB, Jung G. Interferon-γ inhibits hepatitis B virus-induced NF-κB activation through nuclear localization of NF-κB-inducing kinase. Gastroenterology 2005; 128: 2042-53.
45. Park SG, Lee SM, Jung G. Antisense oligodeoxynucleotides targeted against molecular chaperonin Hsp60 block human hepatitis B virus replication. J Biol Chem 2003; 278: 39 851-7.
46. Choi YH, Kim KB, Kim HH et al. FLASH coordinates NF-κB activity via TRAF2. J Biol Chem 2001; 276: 25 073-7.
47. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987; 84: 1005-9.
48. Ryu HM, Park SG, Yea SS, Jang WH, Yang YI, Jung G. Gene expression analysis of primary normal human hepatocytes infected with human hepatitis B virus. World J Gastroenterol 2006; 12: 4986-95.
49. Lin A, Karin M. NF-κB in cancer: A marked target. Semin Cancer Biol 2003; 13: 107-14.
50. Park SG, Lee T, Kang HY, Park K, Cho KH, Jung G. The influence of the signal dynamics of activated form of IKK on NF-κB and anti-apoptotic gene expressions: A systems biology approach. FEBS Lett 2006; 580: 822-30.
51. Gupta SK, Gupta M, Hoffman B, Liebermann DA. Hematopoietic cells from gadd45a-deficient and gadd45b-deficient mice exhibit impaired stress responses to acute stimulation with cytokines, myeloablation and inflammation. Oncogene 2006; 25: 5537-46.
52. Birbach A, Gold P, Binder BR, Hofer E, de Martin R, Schmid JA. Signaling molecules of the NF-κB pathway shuttle constitutively between cytoplasm and nucleus. J Biol Chem 2002; 277: 10 842-51.
53. Kim YS, Schwabe RF, Qian T, Lemasters JJ, Brenner DA. TRAIL-mediated apoptosis requires NF-κB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 2002; 36: 1498-508.
54. Abdollahi A, Lord KA, Hoffman-Liebermann B, Liebermann DA. Sequence and expression of a cDNA encoding MyD118: A novel myeloid differentiation primary response gene induced by multiple cytokines. Oncogene 1991, 6: 165-7.
55. Smith ML, Chen IT, Zhan Q et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994; 266: 1376-80.
56. Vairapandi M, Balliet AG, Fornace AJ Jr, Hoffman B, Liebermann DA. The differentiation primary response gene MyD118, related to GADD45, encodes for a nuclear protein which interacts with PCNA and p21WAF1/CIP1. Oncogene 1996; 12: 2579-94.
57. Kearsey JM, Coates PJ, Prescott AR, Warbrick E, Hall PA. Gadd45 is a nuclear cell cycle regulated protein which interacts with p21Cip1. Oncogene 1995; 11: 1675-83.
58. Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 1998; 95: 521-30.
59. Bernas T, Dobrucki JW. The role of plasma membrane in bioreduction of two tetrazolium salts, MTT, and CTC. Arch Biochem Biophys 2000; 380: 108-16.
60. Arce F, Gatjens-Boniche O, Vargas E, Valverde B, Diaz C. Apoptotic events induced by naturally occurring retinoids ATRA and 13-cis retinoic acid on human hepatoma cell lines Hep3B and HepG2. Cancer Lett 2005; 229: 271-81.
61. Choudhary S, Boldogh S, Garofalo R, Jamaluddin M, Brasier AR. Respiratory syncytial virus influences NF-κB-dependent gene expression through a novel pathway involving MAP3K14/NIK expression and nuclear complex formation with NF-κB2. J Virol 2005; 79: 8948-59.
62. Wu L, Nakano H, Wu Z. The C-terminal activating region 2 of the Epstein-Barr virus-encoded latent membrane protein 1 activates NF-κB through TRAF6 and TAK1. J Biol Chem 2006; 281: 2162-9.
63. Dhawan P, Richmond A. A novel NF-κB-inducing kinase-MAPK signaling pathway up-regulates NF-κB activity in melanoma cells. J Biol Chem 2002; 277: 7920-8.
64. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κ B. Nat Med 1999; 5: 412-17.
65. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-42.
66. Higashitsuji H, Higashitsuji H, Nagao T et al. A novel protein overexpressed in hepatoma accelerates export of NF-κ B from the nucleus and inhibits p53-dependent apoptosis. Cancer Cell 2002; 2: 335-46.
67. Mlynarczuk-Bialy I, Roeckmann H, Kuckelkorn U et al. Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. Cancer Res 2006; 66: 7598-605.